Valeant pays down $811M in senior secured loans after Dendreon Pharma sale

Valeant Pharmaceuticals used $811 million of the $819.9 million it received for selling Dendreon Pharmaceuticals to pay down some of the company's senior secured loans.

Here's what you should know:

1. Valeant has paid all mandatory amortizations through 2019.

2. Since the first quarter of fiscal year 2016, Valeant reduced its debt by more than $4.3 billion.

3. Valeant executives believe the company will pay approximately $5 billion in debt by February 2018.

4. Valeant sold Dendreon Pharmaceuticals to Sanpower Group on June 29. .

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast